ReviewPharmacoEconomics2000
Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio.
Review in PharmacoEconomics, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Management of Persistent Epistaxis Using Floseal Hemostatic Matrix vs. traditional nasal packing: a prospective randomized control trial.Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale · 2018Trial
- Using Evidence from Randomised Controlled Trials in Economic Models: What Information is Relevant and is There a Minimum Amount of Sample Data Required to Make Decisions?PharmacoEconomics · 2018Article
- Multidimensional performance assessment of public sector organisations using dominance criteria.Health economics · 2018Article
- Impact of small study bias on cost-effectiveness acceptability curves and value of information analyses.The European journal of health economics : HEPAC : health economics in prevention and care · 2015Article
- Model-based economic evaluation for medical decision making: learn from the past and prepare for the future.Journal of thoracic disease · 2013Article
- Assessment of viral genotype impact to the cost-effectiveness and overall costs of care for PEG-interferon-2α + ribavirine treated chronic hepatitis C patients.Hepatitis monthly · 2013Article
- Presenting evidence and summary measures to best inform societal decisions when comparing multiple strategies.PharmacoEconomics · 2011Article
- Bayesian decision analysis for choosing between diagnostic/prognostic prediction procedures.Statistics and its interface · 2011Article
- NICE work: how NICE decides what we should pay for.The British journal of general practice : the journal of the Royal College of General Practitioners · 2010Article
- Is chloroquine better than artemisinin combination therapy as first line treatment in adult nigerians with uncomplicated malaria?-A cost effectiveness analysis.African journal of infectious diseases · 2010Article
- Cost-effectiveness of oral appliances in the treatment of obstructive sleep apnoea-hypopnoea.Sleep & breathing = Schlaf & Atmung · 2009Article
- The contrast and convergence of Bayesian and frequentist statistical approaches in pharmacoeconomic analysis.PharmacoEconomics · 2007Review
- Using the net benefit regression framework to construct cost-effectiveness acceptability curves: an example using data from a trial of external loop recorders versus Holter monitoring for ambulatory monitoring of "community acquired" syncope.BMC health services research · 2006Article
- Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation.BMC health services research · 2006Article
- Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme.PharmacoEconomics · 2005Article
- Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies.PharmacoEconomics · 2003Review
- The cost effectiveness of two new antiepileptic therapies in the absence of direct comparative data: a first approximation.PharmacoEconomics · 2003Article
- The probability of cost-effectiveness.BMC medical research methodology · 2002Article
- The potential cost-effectiveness of amblyopia screening programs.Journal of pediatric ophthalmology and strabismusArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this article is to consider Bayesian and frequentist inference methods for measures of incremental cost effectiveness in data obtained via a clinical trial. The most useful measure is the cost-effectiveness (C/E) acceptability curve. Recent publications on Bayesian estimation have assumed a normal posterior distribution, which ignores uncertainty in estimated variances, and suggest unnecessarily complicated methods of computation. We present a simple Bayesian computation for the C/E acceptability curve and a simple frequentist analogue. Our approach takes account of errors in estimated variances, resulting in calculations that are based on distributions rather than normal distributions. If inference is required about the C/E ratio, we argue that the standard frequentist procedures give unreliable or misleading inferences, and present instead a Bayesian interval.
Indexed as
Identifiers
10947489What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.